Ballentine Companions LLC raised its place in shares of Becton, Dickinson and Firm (NYSE:BDX – Free Report) by 11.0% within the third quarter, based on its most up-to-date Type 13F submitting with the Securities and Change Fee. The agency owned 3,291 shares of the medical devices provider’s inventory after shopping for an extra 327 shares in the course of the quarter. Ballentine Companions LLC’s holdings in Becton, Dickinson and Firm had been price $793,000 on the finish of the newest quarter.
Quite a lot of different hedge funds have additionally lately modified their holdings of the enterprise. Nordea Funding Administration AB elevated its stake in shares of Becton, Dickinson and Firm by 277.3% in the course of the first quarter. Nordea Funding Administration AB now owns 1,936,654 shares of the medical devices provider’s inventory valued at $478,295,000 after buying an extra 1,423,353 shares within the final quarter. PineStone Asset Administration Inc. boosted its place in shares of Becton, Dickinson and Firm by 141.6% within the 2nd quarter. PineStone Asset Administration Inc. now owns 1,345,873 shares of the medical devices provider’s inventory price $314,544,000 after buying an extra 788,735 shares within the final quarter. M&G Plc bought a brand new stake in shares of Becton, Dickinson and Firm within the 1st quarter price roughly $173,692,000. First Eagle Funding Administration LLC elevated its place in Becton, Dickinson and Firm by 32.5% in the course of the 2nd quarter. First Eagle Funding Administration LLC now owns 2,803,255 shares of the medical devices provider’s inventory valued at $655,149,000 after shopping for an extra 688,296 shares within the final quarter. Lastly, Financial institution of New York Mellon Corp raised its stake in Becton, Dickinson and Firm by 8.5% in the course of the second quarter. Financial institution of New York Mellon Corp now owns 4,412,163 shares of the medical devices provider’s inventory valued at $1,031,167,000 after shopping for an extra 346,720 shares over the last quarter. Institutional traders personal 86.97% of the corporate’s inventory.
Becton, Dickinson and Firm Inventory Down 0.2 %
BDX opened at $238.13 on Friday. The inventory has a market capitalization of $68.82 billion, a price-to-earnings ratio of 52.45, a PEG ratio of 1.79 and a beta of 0.42. The agency has a 50 day transferring common value of $237.46 and a 200-day transferring common value of $235.15. Becton, Dickinson and Firm has a twelve month low of $218.75 and a twelve month excessive of $259.92. The corporate has a fast ratio of 1.36, a present ratio of 1.85 and a debt-to-equity ratio of 0.70.
Becton, Dickinson and Firm (NYSE:BDX – Get Free Report) final introduced its earnings outcomes on Thursday, August 1st. The medical devices provider reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The enterprise had income of $4.99 billion in the course of the quarter, in comparison with analyst estimates of $5.08 billion. Becton, Dickinson and Firm had a web margin of seven.13% and a return on fairness of 14.49%. The corporate’s quarterly income was up 2.3% in comparison with the identical quarter final 12 months. Throughout the identical interval within the earlier 12 months, the enterprise earned $2.96 EPS. Equities analysis analysts forecast that Becton, Dickinson and Firm will submit 13.11 earnings per share for the present 12 months.
Analysts Set New Value Targets
Quite a lot of analysis corporations have lately commented on BDX. Raymond James lower their goal value on Becton, Dickinson and Firm from $275.00 to $270.00 and set an “outperform” score on the inventory in a analysis notice on Friday, August 2nd. StockNews.com raised shares of Becton, Dickinson and Firm from a “maintain” score to a “purchase” score in a analysis report on Thursday, August eighth. Stifel Nicolaus lifted their goal value on shares of Becton, Dickinson and Firm from $270.00 to $280.00 and gave the inventory a “purchase” score in a report on Friday, July twenty sixth. Citigroup upgraded shares of Becton, Dickinson and Firm from a “impartial” score to a “purchase” score and elevated their value goal for the corporate from $255.00 to $275.00 in a report on Tuesday, October 1st. Lastly, Evercore ISI boosted their value goal on shares of Becton, Dickinson and Firm from $286.00 to $290.00 and gave the inventory an “outperform” score in a report on Tuesday, October 1st. 9 analysis analysts have rated the inventory with a purchase score, Based mostly on information from MarketBeat.com, the corporate presently has a consensus score of “Purchase” and a consensus value goal of $282.63.
Get Our Newest Inventory Evaluation on BDX
Becton, Dickinson and Firm Profile
Becton, Dickinson and Firm develops, manufactures, and sells medical provides, units, laboratory gear, and diagnostic merchandise for healthcare establishments, physicians, life science researchers, medical laboratories, pharmaceutical business, and most people worldwide. The corporate operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Beneficial Tales
Need to see what different hedge funds are holding BDX? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Becton, Dickinson and Firm (NYSE:BDX – Free Report).
Obtain Information & Scores for Becton Dickinson and Firm Every day – Enter your e-mail handle beneath to obtain a concise day by day abstract of the newest information and analysts’ rankings for Becton Dickinson and Firm and associated firms with MarketBeat.com’s FREE day by day e-mail e-newsletter.
